ПОИСК ПО САЙТУ 
поиск по ресурсному центру At its June meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection.
Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is available here.
